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Rome was not built in a day. Likewise, if one considers the
evolution of systemic anti-cancer treatment, it took decades
to go from acceptance of any therapy at all to single agents
achieving isolated tumour responses (without prolongation
of survival) to the current use of combination regimens as ad-
juvant therapy to surgery. Such incremental progress has led
to improved quality of life and eventually survival for patients
with some types of cancer.
Cachexia and skeletal muscle wasting in cancer are signiﬁ-
cant clinical problems of high medical need for a large pro-
portion of cancer patients and associated with very poor
quality of life and very high mortality.1,2 An effective treat-
ment of a complex multifactorial syndrome such as cachexia
will likely evolve from a series of steps of discovery and
new interventions before a comprehensive multimodal strat-
egy can be identiﬁed that improves patient’s quality and
quantity of life.3
There are reasons to be optimistic about the possibility
that in the future, cachexia may be treated effectively. A
number of drugs have already been developed that target
key underlying mechanisms, namely, reduced food intake
and altered metabolism and regulation of muscle mass, with
the latter being split into pro-anabolic and anti-catabolic ap-
proaches. However, there is also some reason to be con-
cerned because of the wide variability in current trial
design, including different inclusion criteria, endpoints, anal-
ysis plans and the deﬁnition of best concomitant supportive
care. Taken to the extreme, such differences in general ap-
proach have resulted in divergent opinions on what to con-
sider a meaningful clinical endpoint by the European
Medicines Agency (EMA) versus the US Food and Drug Ad-
ministration (FDA). A result has been that in the clinical de-
velopment programmes of some drugs, different endpoint
assessments for American versus European regulatory au-
thorities within the same trials using the same source data
have been adopted. An example is the case of the POWER
1 and 2 trials testing the selective androgen receptor modu-
lator enobosarm in patients with cancer suffering from mus-
cle wasting.4–6
There has been a considerable inﬂuence from regulatory
authorities on trial design. In the last 10 years, some regula-
tory authorities have consistently suggested that the design
of randomized controlled trials testing treatments for
cachexia should be aimed at demonstrating appropriate risk
versus beneﬁt, where beneﬁt is deﬁned as concomitant im-
provement in skeletal muscle mass (or lean mass) and rele-
vant/meaningful physical function or improved survival.
Whilst this is an admirable goal, from recent phase III trial re-
sults, this appears to be possibly unachievable with single
modality interventions. Equally, it is not deﬁned to whom
the change is supposed to be ‘meaningful’: patient, caregiver,
doctor, nurse or healthcare provider? The recent phase III tri-
als of enobosarm used a co-primary end-point of lean body
mass and stair climb power.4–6 Based on the FDA agreed
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co-primary responder analysis the trials failed to reach signif-
icance, principally because of lack of beneﬁt in terms of the
functional end point. In the responder analysis demanded
by the FDA, an increase in performance of at least 10% for
stair-climb power test was required for a patient to be con-
sidered to have beneﬁted clinically [paper submitted].
Preventing a decline in performance was not considered in
these analyses. In the analysis suggested by the EMA (which
generally aims to assess clinically meaningful change regard-
less of direction), the same data were analysed using contin-
uous data, and one of the two POWER trials may be
considered successful, as both tests for change in lean mass
and for stair-climb power showed signiﬁcant changes over
time. The two trials also had to be different, because of dif-
ferent background chemotherapy demanded in the inclusion
criteria (i.e. taxane and non-taxane based). It is not clear,
whether these are two trials in two orphan-type cancer indi-
cations (with different results), or are instead two trials in
one indication with inconsistent results. It all depends on
your approach to drug development (and maybe also on
the regulatory body you talk to), but certainly it is a confusing
situation by any standard.
Similarly, the phase III (ROMANA) trials of the ghrelin re-
ceptor agonist anamorelin have shown signiﬁcant beneﬁt in
terms of lean and fat body mass, but not for hand grip
strength.7 These ﬁndings are not completely unexpected
since whilst in healthy young individuals there is a strong
positive correlation between muscle mass and muscle
strength/power per se and between changes thereof,8,9 in
older, sick individuals, the magnitude of strength generated
by a certain unit of mass tends to be lower. These ﬁndings
suggest that preservation/augmentation of muscle mass
does not necessarily always translate into clinical beneﬁts
in non-muscular aspects of the cachexia syndrome as other
factors may remain unchanged from a unimodal approach
(e.g. targeting muscle anabolism). If other aspects of the
cachexia syndrome remain unchanged (like systemic inﬂam-
mation and catabolism or physical inactivity and undernutri-
tion), can unimodal approaches lead to an increase in
physical activity and/or preservation of independence? It
appears that a more comprehensive approach to the ca-
chexia syndrome is warranted if the reference outcomes
of improved physical activity/preservation of independence
are to be pursued. Still, preservation of function (and not
its improvement) may also be a laudable aim of treatment
development in cachexia, and regulatory guidance should
permit for that. However, unlike areas such as hypertension
where a given change in blood pressure is accepted as a
surrogate for clinical events, it has to be recognized that
in cachexia, the ‘relevance’ or ‘meaningfulness’ of a change
in surrogates such as hand grip strength, stair-climb power,
leg extension strength or timed sit-up-and-go is not known.
Perhaps direct measures of patients’ daily physical activity
would be better?
In the related ﬁeld of COPD-associated body wasting, exer-
cise rehabilitation is well established with extensive guideline
recommendations that are evidence-based.10 These guide-
lines have been developed over time and are multimodal in
focus and are explicitly aimed at improving physical function-
ing and physical activity levels, nutritional status and quality
of life. For patients with heart failure, chronic kidney disease,
stroke or ageing-related frailty, such multimodal approaches
are frequently considered,11–13 but evidence is so far weak
compared with what has been achieved in COPD. Novel ther-
apeutic agents under development for cachexia mostly focus
on speciﬁc aspects of the syndrome (e.g. muscle anabolism,
inﬂammation or appetite stimulation).14 Surely, phase III
registration trials should assess safety in general, but efﬁcacy
speciﬁcally in relation to the target of the drug based on its
mechanism of action. It may not be right to discard an
intervention as ineffective because it does not yet affect a
functional outcome, if, in fact – when inserted into a multi-
modal intervention that reﬂects the multifaceted aspect of
the cachexia syndrome – the drug shows extended beneﬁts
that touch on issues such as health-related quality of life,
patient-reported symptoms and tolerance of anti-cancer
therapy.
In the context of a complex disease process and a desire
for multimodal therapies, regulatory advice on co-therapy
with nutrition and exercise is also needed. Suggestions as to
how best to include in this context supportive care in clinical
trials 15 may also be helpful. We understand that this may in-
clude additional clinical trials for food products and support-
ive care approaches and surely this is acceptable, if the rules
of the ‘game’ are clear for the good of our patients. Regula-
tors need to be engaged in encouraging the testing of these
modalities and their systematic inclusion in trial designs. In
heart failure, such activities have already been initiated and
aim to shift the development and authorization of medicines
from the molecule paradigm to their evaluation in the con-
text of the whole healthcare regimen.16 If a trial of a new
agent incorporates these elements and is successful, it can-
not lie with the pharmaceutical company to ensure that such
adjuncts are available in precisely the same format every-
where in the world. Rather, the approved drug label may
need to recommend such adjuncts for optimal effect.
Clearly, this is not an easy ﬁeld for new developments, but
the medical need is great and the commercial returns for
those who make it may be big. Once drugs are approved,
the longer process of incorporating new agents into best clin-
ical practice can begin. It should be clear to pharmaceutical
companies, academic trialists and regulators that they may
need to be more realistic about what can be achieved in a
single step. Maybe also the adaptive licensing approach pro-
posed by EMA 13 can help in this process of developing regu-
latory pathways.
A willingness to consider current data with an open
mind and a ‘Notice on Regulatory Guidance’ on cachexia
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trial design for cancer and beyond that cuts across conti-
nents would be a major step forwards to maintain drug
development momentum, if there is to be genuine prog-
ress at this exciting juncture in the development of
cachexia therapy. We want to help make that a reality
whichever way we can.
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